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Psychiatry

The Use of Propranolol in the Treatment of Post-traumatic Stress Disorder
Tana M Petemian, fou1h·year pharmacy major from Jacksonvdle, N.C . Ahsan L Huet, fourth·year pharmacy rnaior from P1ttslxirgh, Pa.
Sarah E. Drake, fourth-year pharmacy rnapr from Fairlield, Ohio, Jamie L Drees, hfth·year phannacy maior from Canal Wincl-ester, Ohio,
Robert D. Raiff, ftfth·year phamiacy mapr from Westlake, Ohio. B. Shane Martin, PharmD
Abstract
This article exammes the nsmg tsSue of p?St-traumatic stress disorder
(PTSD) and possible treatment options. PTSD is a behavioral disorder
resulting from memory formation and association with a traumatic evenL
A search of the p.iblished literature reveals several positive studies and
case reports suggesting that propranolol, a beta adrenergic receptor
antagonist, may be useful for ooth treatment and prevention of PTSD.
Additionally, current studies are being completed mdifferem populallon
gro!J~ to detenrnne the overall effectiveness and mechanism by which
propranolol is able to provide relief from certain symptoms common to
the disorder. ThJS article d1SCusses the medical evidence and p?ssible
treatment role of propranolol for ~t1ems sufienng from PTSD.
Background
Post-traumatJc stress disorder (PTSD) is defined by DSM-IV as a traumallC
incident in which a person experiences a lrfe-threatening event that involves
extreme fear that IS pers1Stently re-expenenced. 1PTSD is partlcularly
seen mmilitary veterans, including 29 percent of combat veterans and 78
percent of pnsoners of war. Besides military-related causes, automobile accidents account for 56 percent of cases, and personal assault accounts for
35 percent of PTSO cases.2 In order to be diagnosed with PTSD, a patient
must be expeliencing symptomology greater than one month after the
traumatic incident 1Clinical characteristics of PTSD include re-experiencing
symptoms, avoidance of certain situations, and hyperarousal symptoms
along with the possibility otother mJScellaneous symptoms (Table 1).
These characteristics can cause social, occupational and relational
dysfunction. PTSD can be classified based on the occurrence and duraoon
of these charactenstics. If the patient experiences symptoms for less than
three months after the incident, 1t 1s considered acute PTSD. The expenencing of symptoms greater than three months classifies patients as haVlng
chronic PTSO. Finally, a paoont who does not experience these 1nd1cators
until six months alter the event are considered to have delay-onset PTSD.1
Table 1: Classic PTSD Characteristics
Classification
Re -ex~riencing Symporns
Avoidaoce Symporns
Hy~rarousal Symporns

Other Syrnpoms

Examples
Flashbacks, nightmares, frightening thoughts
Staying away from i:Aaces, events and oqects
that are reminders of traumatic event
Easily startled, feeling tense, difficulty
sleeping, angry outbursts
Feeling erootional numbness, guilt, worry,
depression, rnem:iry loss

There are a variety of options for PTSD treatment ranging from pharmacological 1ntervenoons to ~ycholherapy. The first-Ima pharmacologic trearment is the use of selecnve serotonin reuptake inhibitors (SSRls) to reduce
clinical symptoms, including suicidal and aggressive behaviors. Some commonly used FDA-approved SSRls are paroxetine and sertrahne. Psychotherapy can be used man effort lo desensitize PTSD patients to triggers,
which can be anything that reminds patients of the traumatic event, including plac:Gs, sounds and smells. 1•4.S For example, a trigger ror a war veteran
may be the sound of a heltcopter or an unexpected loud noise.6
18
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Rationale and evidence
A current area of research for the treatment of PTSD is the use of
propranolol, a nonselect1ve beta-adrenergic antagonist that crosses the
blood brain barrier. Its current indications include hypertension, angina,
supraventricular arrhythmias, tachycardia, migrame headache prophylaxis and myocardial infarction prevention.4 Propranolol generally has
mild and temporary side effects, including sinus bradycardia, hypotension, lethargy, dimness , nausea and vomiting. Patients with PTSD cyp1cally have higher levels of norepinephnne and epinephrine, which induce
stress. Epinephrine is thought to aid in memory consolidation, playing
a role m the re-experiencing symptoms of PTSD.7 Beta-blockers inhibit
the binding of these neurotransmitcers at the receptors (beta-1 and
beta-2 for epinephrine, beta· 1 for norepmephnne), the proposed clinical
mechanism of propranoloi.&The beta-adrenerg1c system 1s associated
with response and memory forma tion as well as the emotional response
associaled with the memory. Propranolol may both dampen memory
formation and dissociate the memory from the emotional response.
Although this treatment has been termed "forgetllng therapy," it 1s not
meant to make individuals forget their physical experiences but rather
enable them to dissociate the emotions and tears from the memories.9
In a randomized, double-blind study, 19 subpcts were treated with
either propranolol or placebo to determine its effects on PTS0.10 The
patients had been diagnosed with PTSD according to the DSM-IV
criteria. Traumatic events experienced by individuals in this study included childhood sexual abuse, car accidents, rape, hostage situations ,
witnessing or experiencing physical assaults, death threats , and house
fires. The study began with the preparation of two 20-minute written
scnpts that investigators turned into 30-second recordings for each patient, including elements of the traumatic expenences that caused their
PTSD. Patients !hen received either 40 mg ofshon-actJng propranolol
(nine panents) or an ldenucal placebo (10 pa.nenrs). lfthe first dose was
well-tolerated, the study group received 60 mg of long-acnng propranolol
two hours later, while the control group received the placebo. One week
later, patents underwent a script-driven imagery procedure where the
patients listened to the 30-second recorded scripts and were then asked
to tmagtne the event for 30 seconds. Heart rate (HR), skm conductance
(SC) and left corrugator electromyogram (EMG) were recorded. The
responses were calculated by subtracting baseline measurements
from the average measurements taken during the imagery procedure.
Add1tionally, data from a similar previous study of 152 patients with and
without PTSO were included to determine optinal cutoffs for HR, SC and
EMG in PTSD patients. The results of the study show that physiological
responses to mental imagery of the events were significantly smaller in
the propranolol group compared to the placebo. The univariate analysis
showed that HR and SC, but not EMG, responses were significantly
smaller in the propranolol group. The HR and SC responses for the
propranolol group were below the normal cutoffs for PTSD. The placebo
group's responses were still above the normal cutoff. The EMG for both
grou~ fell below the normal cutoff. The study suggests that propranolol
1s effective m controlling physiologic responses to traumabc events m
patients 1f administered after recurrent memones. ThtS evidence lends
support towards the rationale of treating certain PTSD patients with
propranolol.
A casG mport, publishGd in 2002, dGscnbGs thG 9ff9cts of propranolol
on a case of re-emergen t PTSD after retraumatizatton. A 44-year-old
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Caucasian female experienced fiva motor vehicle accidents within a
10-year time frame. Of the five motor vehicle accidents, the last three
caused the pa.Dent to develop PTSD lasting over six months. It was not
untll after the third motor vehicle accident that she immediately began
expenencing severe PTSD symptoms, including recurrent memones
of the event, nightmares, insomnia, flashbacks, irritability and avo1dant
behavior. Over the span of the seven years that the patient suffered from
PTSD, treatment methods included counseling, cognitive and behavioral therapy, and drug regimen trials, including sertraline , im1pramme,
tamazepam and paroxetine with the addition of clonazepam as needed.
The patient's PTSD symptoms persisted over the next three years,
which gradually dissipated and resolved. Forty-eight hours after her SIXth
motor vehicle accident,the patient was prescribed propranolol 60 mg
to be taken orally twice a day. The Clinician-Adminis tered PTSD Scale
(CAPS-Sx) was used to measure changes in PTSD symptoms before,
during and alter the propranolol treatment. Her first CAPS-Sx score was
86 prior to adm1n1Srraoon of the propranolol, at the day-1 1 follow-up
visit. the score had dropped to 56. The patient reported feeling much
improved as quickly as 48 hours after receiving the propranolol and continued to report improvement until her prescription ran out rwo months
later. The patient's PTSD symptoms resurfaced; therefore, her treatment
was resumed. At nine months post-trauma, her CAPS-Sx score was
down to 25. her propranolol was discontinued. and she experienced no
withdrawal side effects or re-emergence of symptoms.11
Future evidence
A 14-week, randomized, double-blind study is currently being conducted
to compare propranolol to placebc treatment in PTSD patients. Patients
will attend an initial visit, where a medical and psychiatric history review
will be obtained, along with a psychiatric interview and symptom questionnaires. Patients with either a DSM-IV diagnosis of PTSD or those
meeting five of the six diagnostic criteria for PTSD will be randomly assigned to take a test dose of propranolol or placebo. Following this, patients will be instructed to take Hie medication subsequent to a traumatic
memory associated with hyperarousal symptoms. The patient will utilize
a maximum of two doses per day mat must be separated by at least six
hours. Patients will also use a cognitive therapy-based workbook to track
symptoms daily as well as any attempts to use cognitive techniques to
relieve symptoms. In addillOn, pabents will attend visits with invesogators
every two weeks to revtew workbcokS with study officials, pick up medi·
cation, d1Scuss side effects, and complete interviews and questionnaires
about symptoms. At the conclus10n of the trial, a CAPS·Sx Seventy
Scale will be administered ro assess PTSD symptom control, and this
will be used as the pnmary outcome measure. Secondary outcomes
will be measured by the Beck Depression lnvento1y, a Post-Traumatic
Scale-Self Score and a Brief Symptoms Inventory-Short Form. 1i
Another randomized, double-blind study being pursued is the use
of propranolol in reducing PTSD symptoms through memory reconsolidation in veterans of the wars in Afghanistan and Iraq. As previously stated, it is thought that epinephrine plays a role in strengthening memory consorldation, which lgads to persistent memory of the
traumatic evem(s) for PTSD patients. The idea behind this study using
propranolot IS to weaken memory reconsolidat1on by using the drug to
block epinephnne bmding. Patients 1n this study will be randomized into
either a non-reactivation propranolol group or a post-reactivation propranolol group. Al Che first v1s1t, non-reactivation propranolol patients will
be given propranolol, and post-reactJvarion propra nolol patients will be
given a placebo. Two days later, both groups will recall their traumalie
event for scnpt preparanon, wliich will trigger the memory reactivation.
The non-reactivation propranolol group will receive a placebo, while the
post-reactlvaoon propranolol group will receive propranolol. The pnmary

outcome measure at week one and six months will be psychophysiotogic
responses to scnpt-drlven imagery. The antic1paoon 1s that the post-react1vaoon propranotol group will exhibit fewer and less severe responses.7
Based on small clinical studies conducted, propranolol may be a viable
treatment option for certain PTSD patients. Compared to pl.acebo, small
chmcal studies have shown propranolol may have significant impact on
PTSD symptoms. especially re-experiencing and hyperarousal symptoms.
Studies comparing it to other treatment options (SSRls. tricyclic antidepressants and MAO inhibitors) are limited, and more research needs to be
conducted. Propranolol is not currently a first-line therapy, but for those
patients that are unresponsive to othertreatment options. it should be
considered as a means to manage PTSD symptoms.
This is an area of increasing importance to study due to the prevalence
of war veterans returning home. PTSD is thought to occur in 11-20 percent
of veterans of the wars in Afghanistan and Iraq. PTSD has an impact on
quality of life for veterans and their families. Veterans who suffer from
thlS disease may be more prone to develop substance abuse problems,
personality disturbances and cnminal behavior compared ro the general
population. Another problem that the veterans face IS su1cldal tendenc1es. 13
As troops con tinue to be deployed, it is important to explore new treatment
opoons since the numbers of PTSD patients is likely to increase. Besides
treatment, studies are being conducted to research propranolol in the
prevenaon of PTSD, which may be beneficial ;o m11ttary personnel as well
as the c1v11ian population. However, the prophylactic use of propranotol in
the mffitary IS controvers1al. 9
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